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Increasing incidence of multi-drug 
resistant organisms (MDROs): 
An emerging global concern
Zohra Chaudhry MD, Hind Hadid MD, Mary B Perri MT, Marcus Zervos MD, Indira Brar MD
Infectious Disease, Henry Ford Health System, Detroit, Michigan
Introduction:
• With massive efflux of civilians from violence-stricken countries, the high 
rates of colonization with multidrug-resistant organisms (MDROs) 
amongst the refugees is an emerging global concern. 
• Our case report describes two Middle Eastern patients
• suffered severe traumatic injuries in their home countries, 
• subsequently developing chronic wounds. 
• Upon arrival to the United States, the patients sought treatment in our 
institution for wound infection with MDRO 
Objectives:
1. Describe the patients’ clinical characteristics and risk factors for 
MDRO colonization.  
2. Elucidate the susceptibility pattern of bacterial isolates from our 
patients, highlighting how our experimental studies helped 
choosing antibiotic therapy.
3. Describe the treatment and clinical outcome of the patients.
Materials and Methods:
• Clinical data was collected from the patients’ charts 
• Identification (MALDI-TOF® MS, bioMerieux, Inc., Durham, NC) and susceptibility 
(Vitek-2 ®, bioMerieux, Inc., Durham, NC) of the organisms from the wound performed 
as part of routine identification/susceptibility test in the clinical microbiology 
laboratory. 
• MICs performed by manual microbroth dilution according to Clinical and Laboratory 
Standards Institute (CLSI) guidelines. 
• Time kill curves used to determine in vitro synergy of Pseudomonas aeruginosa isolate 
in antibiotic combinations:
• ½ x MIC meropenem plus ½ x MIC colistin, 
• ½ x MIC meropenum plus ½ x MIC colistin plus ½ x MIC rifampin, and 
• ½ x MIC meropenem plus ½ x MIC ceftazidime/avibactam utilizing a starting inoculum of 105 
CFU/ml. 
Materials and methods:
• Mueller Hinton II broth (Becton, Dickenson and Co., Sparks, MD) was 
used (Table 1). 
• Antibiotics prepared at 100X concentration being tested in two or 
three tubes:
• with each ½ x MIC antibiotic alone, 
• a synergy tube with combination of  two or three ½ x MIC antibiotics and
• growth control tube 
• Samples were serially diluted at 0, 4 and 24 hours and 
• plated on TSA II agar (Becton, Dickinson, and Co., Sparks, NC).
MIC Mero MIC Mero used MIC Col MIC Col used MIC Rif MIC Rif used MIC Ceft/avi MIC Ceft/avi used Synergy
102053 16 8 1 0.5 No
102053 16 8 1 0.5 32 16 Yes
102053 16 8 32 16 No
(Table 1) 
Materials and methods:
Figure 1: Time kill synergy curve of synergistic combination of meropenem, 
colistin and rifampin
• Time kill curves were constructed by 
plotting colony counts over time, 
• With synergy being defined as:
• ≥2-log10 decrease in CFU/ml 
between the combination and its 
most active constituent after 24hrs, 
• the number of surviving organisms 
in the presence of combination 
must be ≥2 log10 CFU/ml below 
the starting inoculum
Results:
• Patient 1 came from Syria
• Patient 2 from Yemen
• Both patients’ wound infections were healthcare-associated, 
• with underlying chronic osteomyelitis
• Both had multiple risk factors for MDRO, including multiple prior 
surgeries and antibiotic courses.  
Culture & Susceptibility 
PSEUDOMONAS AERUGINOSA
Antibiotic Kirby Bauer Microscan
Amikacin Resistant Resistant
Aztreonam Resistant Resistant
Cefepime Resistant >=64 
Resistant
Ceftazidime Avibact Resistant Resistant
Ceftolozane Tazobactam Resistant Resistant
Ciprofloxacin Resistant >=4
Resistant
Colistin Susceptible 0.5 
Susceptible
Fosfomycin Intermediate 96
Intermediate
Gentamicin Resistant >=16
Resistant
Meropenem Resistant >=16
Resistant
Piperacillin/Tazobactam Resistant Resistant
Tobramycin Resistant >=16
Resistant
Results:
• Patient 1 culture grew:
• CRE Klebsiella
• MDR Morganella, and 
• on a later date, ESBL 
Escherichia coli. 
• Patient 2 culture grew:
• CRE Pseudomonas 
aeruginosa, sensitive only 
to colistin (Figure 2). 
(Figu
re
 2
). 
Results:
• Patient 1 was treated with ceftazidime-avibactam
• Patient 2 received rifampin + meropenem + colistin, 
• the only antibiotic combination demonstrating in-vitro synergistic killing (Figure 1). 
• Both patients required prolonged therapy up to to 6-weeks
• Doing well on follow up
Conclusions:
• Colonization with MDRO amongst Middle Eastern immigrants is an 
alarming phenomenon. 
• In-vitro experiments with available antibacterial agents may assist in 
the choice of therapy for MDRO strains when conventional options 
are exhausted.
Questions?
Thank you!
